JP2015504072A5 - - Google Patents

Download PDF

Info

Publication number
JP2015504072A5
JP2015504072A5 JP2014551313A JP2014551313A JP2015504072A5 JP 2015504072 A5 JP2015504072 A5 JP 2015504072A5 JP 2014551313 A JP2014551313 A JP 2014551313A JP 2014551313 A JP2014551313 A JP 2014551313A JP 2015504072 A5 JP2015504072 A5 JP 2015504072A5
Authority
JP
Japan
Prior art keywords
composition
compound
cell
compound according
mammal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014551313A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015504072A (ja
JP5747137B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/020124 external-priority patent/WO2013103703A1/en
Publication of JP2015504072A publication Critical patent/JP2015504072A/ja
Publication of JP2015504072A5 publication Critical patent/JP2015504072A5/ja
Application granted granted Critical
Publication of JP5747137B2 publication Critical patent/JP5747137B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014551313A 2012-01-03 2013-01-03 Iapの阻害剤 Active JP5747137B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261582760P 2012-01-03 2012-01-03
US61/582,760 2012-01-03
PCT/US2013/020124 WO2013103703A1 (en) 2012-01-03 2013-01-03 Inhibitors of iap

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015096425A Division JP2015199738A (ja) 2012-01-03 2015-05-11 Iapの阻害剤

Publications (3)

Publication Number Publication Date
JP2015504072A JP2015504072A (ja) 2015-02-05
JP2015504072A5 true JP2015504072A5 (enExample) 2015-03-26
JP5747137B2 JP5747137B2 (ja) 2015-07-08

Family

ID=48695302

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014551313A Active JP5747137B2 (ja) 2012-01-03 2013-01-03 Iapの阻害剤
JP2015096425A Pending JP2015199738A (ja) 2012-01-03 2015-05-11 Iapの阻害剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015096425A Pending JP2015199738A (ja) 2012-01-03 2015-05-11 Iapの阻害剤

Country Status (41)

Country Link
US (6) US8716236B2 (enExample)
EP (2) EP2800749B1 (enExample)
JP (2) JP5747137B2 (enExample)
KR (3) KR101553792B1 (enExample)
CN (2) CN104159897A (enExample)
AR (2) AR089623A1 (enExample)
AU (1) AU2013202780B2 (enExample)
BR (1) BR112014016637B1 (enExample)
CA (1) CA2861637C (enExample)
CL (1) CL2014001770A1 (enExample)
CO (1) CO7020915A2 (enExample)
CR (1) CR20140367A (enExample)
CY (2) CY1118371T1 (enExample)
DK (2) DK3133073T3 (enExample)
EC (1) ECSP14011792A (enExample)
ES (2) ES2672809T3 (enExample)
HK (1) HK1203949A1 (enExample)
HR (2) HRP20161381T1 (enExample)
HU (2) HUE037760T2 (enExample)
IL (2) IL233386A (enExample)
LT (2) LT2800749T (enExample)
MA (1) MA35895B1 (enExample)
ME (2) ME03084B (enExample)
MX (1) MX336294B (enExample)
MY (1) MY178390A (enExample)
NO (1) NO2755614T3 (enExample)
NZ (1) NZ627480A (enExample)
PE (1) PE20142182A1 (enExample)
PH (2) PH12014501534B1 (enExample)
PL (2) PL2800749T3 (enExample)
PT (2) PT2800749T (enExample)
RS (2) RS55327B1 (enExample)
RU (2) RU2593259C2 (enExample)
SG (1) SG11201403784QA (enExample)
SI (2) SI3133073T1 (enExample)
SM (2) SMT201800352T1 (enExample)
TR (1) TR201808088T4 (enExample)
TW (1) TWI503318B (enExample)
UA (1) UA114417C2 (enExample)
WO (1) WO2013103703A1 (enExample)
ZA (1) ZA201405535B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2755614T3 (enExample) 2012-01-03 2018-03-31
WO2016079527A1 (en) 2014-11-19 2016-05-26 Tetralogic Birinapant Uk Ltd Combination therapy
WO2016097773A1 (en) 2014-12-19 2016-06-23 Children's Cancer Institute Therapeutic iap antagonists for treating proliferative disorders
CN109705191B (zh) * 2017-10-25 2022-04-29 广东东阳光药业有限公司 Iap抑制剂及其在药物中的应用
WO2019091492A1 (zh) * 2017-11-13 2019-05-16 南京明德新药研发股份有限公司 用作iap抑制剂的smac模拟物及其用途
JP7515175B2 (ja) 2018-07-31 2024-07-12 ファイメクス株式会社 複素環化合物
US20220402935A1 (en) 2019-07-31 2022-12-22 Fimecs, Inc. Heterocyclic compound
US20230029259A1 (en) * 2019-12-02 2023-01-26 Ascentage Pharma (Suzhou) Co., Ltd. Combination of iap inhibitors and parp or mek inhibitors or other chemotherapeutic agents
WO2021148396A1 (en) 2020-01-20 2021-07-29 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
US20230233691A1 (en) 2021-10-22 2023-07-27 University Of Houston System Methods and compositions for treating chronic inflammatory injury, metaplasia, dysplasia and cancers of epithelial tissues

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4526988A (en) 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
EP0975608B1 (en) 1997-04-15 2005-06-15 Genentech, Inc. Halo-alkoxycarbonyl prodrugs
MXPA06014969A (es) 2004-07-02 2007-02-08 Genentech Inc Inhibidores de iap.
ATE477254T1 (de) * 2004-12-20 2010-08-15 Genentech Inc Pyrrolidine als inhibitoren von iap
RU2009117701A (ru) * 2006-10-12 2010-11-20 Новартис АГ (CH) Производные пирролидина в качестве ингибиторов iap
CN101687787A (zh) 2007-04-30 2010-03-31 健泰科生物技术公司 Iap的抑制剂
NO2755614T3 (enExample) 2012-01-03 2018-03-31
USD690416S1 (en) 2012-12-12 2013-09-24 Pharmajet, Inc. Needle-free syringe

Similar Documents

Publication Publication Date Title
JP2015504072A5 (enExample)
HRP20161381T1 (hr) Inhibitori iap
JP2011251990A5 (enExample)
JP2010526079A5 (enExample)
HRP20201681T1 (hr) Inhibitor aurora a kinaze
JP2019512478A5 (enExample)
EA201290482A1 (ru) Стабильные составы для лиофилизации терапевтических частиц
JP2016519062A5 (enExample)
SI2970216T1 (en) Biaryl-amide compounds as kinase inhibitors
HK1203927A1 (en) Heterocyclic compounds and uses as anticancer agents
EA201100794A1 (ru) Замещенные пиримидины, предназначенные для лечения заболеваний, таких как рак
JP2019513734A5 (enExample)
JP2013509429A5 (enExample)
EA201201661A1 (ru) Новые аминопиразолохиназолины
AU2014233520A1 (en) Modulators of the eIF2alpha pathway
EA201391395A1 (ru) Терапевтические соединения
EA200901133A1 (ru) Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
SI2820009T1 (en) Serine / Threonine kinase inhibitors
EA201001196A1 (ru) Соединения 4-пиридинона и их применение для лечения рака
EA201590879A1 (ru) Арилконденсированные и гетероарилконденсированные лактамы
EA201171151A1 (ru) Кристаллические трипептидные ингибиторы эпоксикетон-протеазы
EA201390772A1 (ru) Новые соли и полиморфные формы афатиниба
CY1119746T1 (el) Φαρμακευτικες μορφοποιησεις που περιεχουν ριφαξιμινη, διαδικασιες για τη ληψη τους και μεθοδος αγωγης εντερικων νοσων
EA201000550A1 (ru) Производные тиазола
JP2015500885A5 (enExample)